Interesting acquisition. No doubt helpful for Neuren to have someone on deck with relevant experience in Phase 3 development and New Drug Applications.
I wonder if it's a vote of confidence in NNZ-2591 from DeKarske.
I also wonder about the implications (if any) for Neuren and Acadia's relationship. It seems unlikely that Neuren would 'poach' someone who is actively helping Acadia with trofinetide.
Perhaps there is an element of collaboration to progress NNZ-2591 towards approval.
Interesting acquisition. No doubt helpful for Neuren to have...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.63 |
Change
-0.070(0.42%) |
Mkt cap ! $2.095B | |||
| Open | High | Low | Value | Volume |
| $16.68 | $16.86 | $16.51 | $4.012M | 240.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 982 | $16.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.66 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |